AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...
The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...
In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...
(Reuters) -AbbVie has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's unit for ...
Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of ...
AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement ...
SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects. "As a leader in hematologic malignancies, AbbVie is ...
SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects. "As a leader in hematologic malignancies, AbbVie is ...